The new industrial facility, which will gauge around 100,000 square meters, will require four years and two stages to assemble. The new grounds is important for VectorBuilder's push to grow its R&D abilities and creation limit. With 30 creation suites, intended to make certain bio items utilized in making vector-based antibodies, similar to plasmids, mRNA, AAV, lentivirus and cell line, the new grounds will grow VectorBuilder's R&D abilities and creation limit and is supposed to get 2,000 staff individuals. Other than increasing its assembling capacities, the new office will have an exploration foundation to chip away at growing new and better quality conveyance advancements to fulfill need in clinical applications like quality treatment, vector-based immunizations and infection based disease therapeutics, as indicated by VectorBuilder. There will likewise be a spot to prepare researchers and architects in the quality conveyance field. VectorBuilder centers around making quality treatments from vectors. The utilization of vectors in quality treatment has been eased back by challenges in sorting out some way to make them. Notwithstanding, VectorBuilder's serious spotlight on creating vectors to be utilized in quality treatment is by all accounts paying off. The organization flaunts clients, for example, Novartis and the MD Anderson Cancer Center. 

“Some experts predict that in 10 to 20 years, vector-based drugs will become the third pillar of medicine, after small-molecule drugs and protein-based biologics,” said Dr. Bruce Lahn, chief scientist at VectorBuilder. “We are therefore expanding our R&D capabilities, as well as our manufacturing capacity, to continue leading the way in the development of innovative gene delivery technologies that will make research more efficient, and genetic medicine more effective and affordable.”

The growth is part of VectorBuilder’s plan for global expansion. The company has future sites planned in the U.S., Europe and Japan.